Investigational drug · Phase 2
GenSci134
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pediatric Growth Hormone Deficiency, Idiopathic Short Stature.
Phase 2Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "GenSci134"
First trial start
2026
Mar 6, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GenSci134", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pediatric Growth Hormone Deficiency
- Idiopathic Short Stature
Approved drugs for the same conditions: Growth hormone deficiency · Rare and genetic disease · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "GenSci134" as an intervention, largest first.
- A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)Pivotal-lookingNot yet recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07450053 · 128 participants (planned) · Start Mar 6, 2026 · Primary completion Jul 18, 2028
Drug: GenSci134 Injection; Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®) · For: Idiopathic Short Stature
Sites: Wuhan, China
- A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)Pivotal-lookingNot yet recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07450001 · 128 participants (planned) · Start Mar 6, 2026 · Primary completion Jul 18, 2028
Drug: GenSci134 Injection; Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®) · For: Pediatric Growth Hormone Deficiency
Sites: Wuhan, China
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07016802 · 64 participants (planned) · Start Jun 9, 2025 · Primary completion Nov 25, 2026
Drug: GenSci134; Placebo and 1 more · For: Safety; Tolerability; Adult Growth Hormone Deficiency
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.